Abstracts

789 – Assessment of Total and Unbound Cabotegravir Pharmacokinetics Among Pregnant Women in HPTN 084

Background HPTN 084 found that long-acting cabotegravir (CAB-LA) significantly reduced the risk of HIV acquisition in women compared to tenofovir disoproxil fumarate/emtricitabine (TDF/FTC).  In the HPTN 084 open label extension, participants consented to CAB-LA injections during pregnancy.  A nested sub-study evaluated the pharmacokinetics of total and unbound (bioavailable) CAB among a subset of participants who…

570 – Extent and Impact of APOBEC3 Editing on HIV-1 Proviral DNA Drug Resistance

Background APOBEC3-mediated G-to-A hypermutation in HIV-1 proviral DNA complicates drug resistance interpretation. Its extent varies across sequences. Available tools can detect but cannot differentiate mutations driven by drug pressure from APOBEC3 editing. Thresholds and criteria for excluding hypermutated sequences are undefined, limiting interpretation and clinical decision-making.  Methods We sequenced near-full-length (nFL) HIV-1 proviral genomes from…

606 – Elevated Triglyceride and Ceramide Metabolites in MASLD Among PWH

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over one-third of people with HIV (PWH), yet underlying mechanisms and metabolic signatures remain poorly defined. Dysregulated lipid metabolism may play a key role. This study aimed to identify distinctive plasma lipid metabolite patterns in PWH with MASLD. Methods We conducted a matched case-control study of 50…

1086 – CAB/LEN for Postpartum Women in South Africa & Côte d’Ivoire: Clinical Impact and Cost-Effectiveness

Background Cabotegravir/lenacapavir (CAB/LEN) may reduce ART adherence barriers for breastfeeding (BF) women with HIV, improving maternal health and reducing vertical transmission (VT). Using CEPAC, a validated computer model of mother-child pairs, we estimate the clinical outcomes and cost-effectiveness of CAB/LEN for BF women in South Africa and Côte d’Ivoire. Methods For each country, we simulated…

1089 – Modeled Comparison of Well-Being and Quality-Adjusted-Life-Years as HIV Outcomes in Southern Africa

Background Well-being-adjusted life-years (WALYs), an emerging metric, broaden quality-adjusted life-years (QALYs) by considering factors relevant for health policy decision making that extend beyond health-related quality-of-life (HRQoL). We compared results and inferences for decision making using WALYs versus QALYs in an allocative efficiency analysis of HIV-related interventions in southern African countries. Methods Using a validated simulation…

640 – Distribution of High Resolution Anoscopists in the United States

Background Anal cancer disproportionately affects people with HIV (PWH) and is preventable via ablation of high-grade dysplasia through high-resolution anoscopy (HRA). Performing HRAs requires specific training not routinely offered by any subspecialty and are often performed by infectious disease, surgery, gastroenterology and gynecology subspecialists, among others. Anal cancer screening with HRAs is now recommended by…

665 – CMKLR1 as a Potential Target of Atherosclerotic Cardiovascular Disease in PLWH

Background People living with HIV (PLWH) have a two-fold higher risk of developing atherosclerotic cardiovascular disease compared with people without HIV (PWoH). Chronic immune activation and adipose dysfunction are thought to contribute, yet the underlying mechanisms remain incompletely defined. Chemerin is an adipokine that regulates immune responses, adipose biology, and metabolic processes through its receptors…